BAKER BROS ADVISORS LLC Insider Trading Transactions
Get free email notifications about insider trading for BAKER BROS ADVISORS LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of BAKER BROS ADVISORS LLC. BAKER BROS ADVISORS LLC is 10% Owner in BIOCRYST PHARMACEUTICALS INC ($BCRX) and Director in INCYTE CORP ($INCY) and Director in ALEXION PHARMACEUTICALS INC ($ALXN) and 10% Owner in IDERA PHARMACEUTICALS, INC. ($IDRA) and Director in IDERA PHARMACEUTICALS, INC. ($IDRA) and in XOMA Corp ($XOMA) and Director in ACADIA PHARMACEUTICALS INC ($ACAD) and Director in SEATTLE GENETICS INC /WA ($SGEN) and Director in GENOMIC HEALTH INC ($GHDX) and 10% Owner in BELLICUM PHARMACEUTICALS, INC ($BLCM) and 10% Owner in AQUINOX PHARMACEUTICALS, INC ($AQXP) and Director in AQUINOX PHARMACEUTICALS, INC ($AQXP) and Director in Zymeworks Inc. ($ZYME) and Director in Kodiak Sciences Inc. ($KOD) and 10% Owner in Invitae Corp ($NVTA) and Director in IGM Biosciences, Inc. ($IGMS) and 10% Owner in Atreca, Inc. ($BCEL) and in Mirati Therapeutics, Inc. ($MYG) and 10% Owner in Mirati Therapeutics, Inc. ($MYG) and Director in Talis Biomedical Corp ($TLIS) and Director in Aeglea BioTherapeutics, Inc. ($AGLE) and in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and in Intellia Therapeutics, Inc. ($NTLA) and Director in BeiGene, Ltd. ($BGNE) and Director in Prelude Therapeutics Inc ($PRLD) and Director in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and in HOOKIPA Pharma Inc. ($HOOK).
Latest Insider Trading Transactions of BAKER BROS ADVISORS LLC
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACAD, AGLE, ALXN, BCEL, BGNE, BLCM, BCRX, GHDX, HOOK, IDRA, IGMS, INCY, NTLA, NVTA, KNSA, KOD, MYG, NLTX, PRLD, RYTM, SGEN, TLIS, XOMA, ZYME
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 13 2021 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 11.40 | 25,000 | 285,000 | 25,000 | |
Feb 25 2021 | AGLE | Aeglea BioTherapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 7.11 | 47,200 | 335,592 | 47,200 | |
Feb 23 2021 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 91.50 | 6,423 | 587,705 | 6,423 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 6,427,576 | 0 | 27,511,741 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 536,438 | 0 | 2,345,481 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 7,286,794 | 0 | 21,084,165 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 536,414 | 0 | 1,809,043 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 1,941 | 0 | 5,420 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 6,654,603 | 0 | 13,797,371 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 598,860 | 0 | 1,272,629 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 7,142,768 | 0 | 7,142,768 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 673,769 | 0 | 673,769 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 3,479 | 0 | 3,479 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 9,191,433 | 0 | 0 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 767,106 | 0 | 0 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 10,420,117 | 0 | 0 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 767,072 | 0 | 0 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 2,776 | 0 | 0 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 9,516,082 | 0 | 0 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 856,370 | 0 | 0 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 10,214,159 | 0 | 0 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 963,490 | 0 | 0 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 0.00 | 4,975 | 0 | 0 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 0.00 | 9,191,433 | 0 | 9,191,433 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 0.00 | 767,106 | 0 | 767,106 | |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 16.00 | 5,792,538 | 92,680,608 | 7,003,176 | 1.2 M to 7 M (+478.47 %) |
Feb 19 2021 | TLIS | Talis Biomedical C ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 16.00 | 457,462 | 7,319,392 | 571,659 | 114.2 K to 571.7 K (+400.59 %) |
Jan 29 2021 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 12.85 | 5,188 | 66,666 | 41,500 | |
Jan 29 2021 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 12.85 | 5,188 | 66,666 | 41,500 | |
Jan 29 2021 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Buy | M | 12.85 | 5,188 | 66,666 | 9,252,951 | 9.2 M to 9.3 M (+0.06 %) |
Jan 29 2021 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Buy | M | 12.85 | 5,188 | 66,666 | 876,061 | 870.9 K to 876.1 K (+0.60 %) |
Jan 29 2021 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 40.27 | 5,833 | 234,895 | 2,527 | |
Jan 29 2021 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 40.27 | 5,833 | 234,895 | 2,527 | |
Jan 29 2021 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 16.00 | 5,377 | 86,032 | 6,723 | |
Jan 29 2021 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 16.00 | 5,377 | 86,032 | 6,723 | |
Jan 29 2021 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Buy | M | 40.27 | 5,833 | 234,895 | 2,895,306 | 2.9 M to 2.9 M (+0.20 %) |
Jan 29 2021 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Buy | M | 40.27 | 5,833 | 234,895 | 272,898 | 267.1 K to 272.9 K (+2.18 %) |
Jan 29 2021 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Buy | M | 16.00 | 5,377 | 86,032 | 2,889,473 | 2.9 M to 2.9 M (+0.19 %) |
Jan 29 2021 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Buy | M | 16.00 | 5,377 | 86,032 | 267,065 | 261.7 K to 267.1 K (+2.05 %) |
Jan 13 2021 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | P | 0.00 | 154,222 | 0 | 5,212,371 | |
Jan 13 2021 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | P | 0.00 | 12,444 | 0 | 509,480 | |
Dec 23 2020 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | P | 0.00 | 518,555 | 0 | 10,283,888 | |
Dec 23 2020 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | P | 0.00 | 38,974 | 0 | 1,199,122 | |
Dec 23 2020 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 15.25 | 394,360 | 6,013,990 | 3,501,691 | 3.1 M to 3.5 M (+12.69 %) |
Dec 23 2020 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 15.25 | 29,640 | 452,010 | 320,049 | 290.4 K to 320 K (+10.21 %) |
Dec 11 2020 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | P | 0.01 | 616,846 | 6,168 | 616,846 | |
Dec 11 2020 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | P | 0.01 | 49,820 | 498 | 49,820 | |
Dec 04 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Sell | S | 220.50 | 1,386,033 | 305,620,277 | 10,811,048 | 12.2 M to 10.8 M (-11.36 %) |
Dec 04 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Sell | S | 220.50 | 125,513 | 27,675,617 | 979,003 | 1.1 M to 979 K (-11.36 %) |
Dec 04 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Gift | G | 0.00 | 13,516 | 0 | 10,418 | 23.9 K to 10.4 K (-56.47 %) |
Dec 04 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Gift | G | 0.00 | 13,516 | 0 | 10,418 | 23.9 K to 10.4 K (-56.47 %) |
Oct 05 2020 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 223 | 0 | 2,883,873 | 2.9 M to 2.9 M (+0.01 %) |
Oct 05 2020 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 223 | 0 | 261,465 | 261.2 K to 261.5 K (+0.09 %) |
Oct 02 2020 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 317 | 0 | 29,313,809 | 29.3 M to 29.3 M (0.00 %) |
Oct 02 2020 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 317 | 0 | 2,850,042 | 2.8 M to 2.9 M (+0.01 %) |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 382,884 | 0 | 5,058,149 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 382,884 | 0 | 0 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 30,349 | 0 | 497,036 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 30,349 | 0 | 0 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 574,327 | 0 | 0 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 45,524 | 0 | 0 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 2,698,424 | 0 | 4,675,265 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 2,698,424 | 0 | 0 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 247,034 | 0 | 466,687 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 247,034 | 0 | 0 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 4,047,634 | 0 | 0 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 370,552 | 0 | 0 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 1,976,841 | 0 | 1,976,841 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 1,976,841 | 0 | 0 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 219,653 | 0 | 219,653 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 219,653 | 0 | 0 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 2,965,263 | 0 | 0 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 329,478 | 0 | 0 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 12.85 | 46,688 | 599,941 | 46,688 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | P | 0.00 | 957,211 | 0 | 957,211 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | P | 0.00 | 75,873 | 0 | 75,873 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | P | 0.00 | 3,373,029 | 0 | 3,373,029 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | P | 0.00 | 308,793 | 0 | 308,793 | |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 19.00 | 1,474,319 | 28,012,061 | 9,247,763 | 7.8 M to 9.2 M (+18.97 %) |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 19.00 | 104,628 | 1,987,932 | 870,873 | 766.2 K to 870.9 K (+13.65 %) |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 574,327 | 0 | 7,773,444 | 7.2 M to 7.8 M (+7.98 %) |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 45,524 | 0 | 766,245 | 720.7 K to 766.2 K (+6.32 %) |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 4,047,634 | 0 | 7,199,117 | 3.2 M to 7.2 M (+128.44 %) |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 370,552 | 0 | 720,721 | 350.2 K to 720.7 K (+105.82 %) |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 2,965,263 | 0 | 3,151,483 | 186.2 K to 3.2 M (+1,592.34 %) |
Sep 30 2020 | PRLD | Prelude Therapeuti ... | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 329,478 | 0 | 350,169 | 20.7 K to 350.2 K (+1,592.37 %) |
Sep 25 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 58.09 | 7,843 | 455,565 | 11,324,937 | 11.3 M to 11.3 M (+0.07 %) |
Sep 25 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 58.09 | 557 | 32,354 | 1,027,238 | 1 M to 1 M (+0.05 %) |
Sep 25 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 56.92 | 19,235 | 1,094,854 | 11,317,094 | 11.3 M to 11.3 M (+0.17 %) |
Sep 25 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 56.92 | 1,365 | 77,696 | 1,026,681 | 1 M to 1 M (+0.13 %) |
Sep 25 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 56.76 | 4,705 | 267,055 | 11,297,859 | 11.3 M to 11.3 M (+0.04 %) |
Sep 25 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 56.76 | 334 | 18,958 | 1,025,316 | 1 M to 1 M (+0.03 %) |
Sep 25 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 55.35 | 13,153 | 728,057 | 11,293,154 | 11.3 M to 11.3 M (+0.12 %) |
Sep 25 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 55.35 | 933 | 51,644 | 1,024,982 | 1 M to 1 M (+0.09 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 52.11 | 29,327 | 1,528,374 | 11,280,001 | 11.3 M to 11.3 M (+0.26 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 52.11 | 2,081 | 108,451 | 1,024,049 | 1 M to 1 M (+0.20 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 51.41 | 4,306 | 221,368 | 11,250,674 | 11.2 M to 11.3 M (+0.04 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 51.41 | 306 | 15,731 | 1,021,968 | 1 M to 1 M (+0.03 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 52.44 | 74,381 | 3,900,235 | 11,246,368 | 11.2 M to 11.2 M (+0.67 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 52.44 | 5,278 | 276,757 | 1,021,662 | 1 M to 1 M (+0.52 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 52.40 | 10,467 | 548,468 | 11,171,987 | 11.2 M to 11.2 M (+0.09 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 52.40 | 743 | 38,933 | 1,016,384 | 1 M to 1 M (+0.07 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 51.97 | 1,120 | 58,206 | 11,161,520 | 11.2 M to 11.2 M (+0.01 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 51.97 | 80 | 4,158 | 1,015,641 | 1 M to 1 M (+0.01 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 51.98 | 22,361 | 1,162,235 | 11,160,400 | 11.1 M to 11.2 M (+0.20 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 51.98 | 1,587 | 82,486 | 1,015,561 | 1 M to 1 M (+0.16 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 50.15 | 36,647 | 1,837,909 | 11,138,039 | 11.1 M to 11.1 M (+0.33 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 50.15 | 2,601 | 130,445 | 1,013,974 | 1 M to 1 M (+0.26 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 49.72 | 10,983 | 546,102 | 11,101,392 | 11.1 M to 11.1 M (+0.10 %) |
Sep 24 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 49.72 | 779 | 38,734 | 1,011,373 | 1 M to 1 M (+0.08 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.47 | 15,172 | 720,200 | 11,090,409 | 11.1 M to 11.1 M (+0.14 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.47 | 1,220 | 57,912 | 1,010,594 | 1 M to 1 M (+0.12 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.39 | 76,473 | 3,623,857 | 11,075,237 | 11 M to 11.1 M (+0.70 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.39 | 6,151 | 291,480 | 1,009,374 | 1 M to 1 M (+0.61 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.04 | 15,807 | 743,482 | 10,998,764 | 11 M to 11 M (+0.14 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.04 | 1,272 | 59,829 | 1,003,223 | 1 M to 1 M (+0.13 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 45.88 | 185 | 8,487 | 10,982,957 | 11 M to 11 M (0.00 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 45.88 | 15 | 688 | 1,001,951 | 1 M to 1 M (0.00 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.50 | 9,101 | 432,281 | 10,982,772 | 11 M to 11 M (+0.08 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.50 | 712 | 33,819 | 1,001,936 | 1 M to 1 M (+0.07 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.26 | 26,238 | 1,239,984 | 10,973,671 | 10.9 M to 11 M (+0.24 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.26 | 2,054 | 97,070 | 1,001,224 | 999.2 K to 1 M (+0.21 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 46.62 | 29,319 | 1,366,767 | 10,947,433 | 10.9 M to 10.9 M (+0.27 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 46.62 | 2,295 | 106,986 | 999,170 | 996.9 K to 999.2 K (+0.23 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 45.30 | 12,132 | 549,535 | 10,918,114 | 10.9 M to 10.9 M (+0.11 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 45.30 | 950 | 43,031 | 996,875 | 995.9 K to 996.9 K (+0.10 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 49.00 | 32,088 | 1,572,312 | 10,905,982 | 10.9 M to 10.9 M (+0.30 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 49.00 | 2,512 | 123,088 | 995,925 | 993.4 K to 995.9 K (+0.25 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.60 | 77,456 | 3,686,658 | 10,873,894 | 10.8 M to 10.9 M (+0.72 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.60 | 6,062 | 288,532 | 993,413 | 987.4 K to 993.4 K (+0.61 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.45 | 2,987 | 141,725 | 10,796,438 | 10.8 M to 10.8 M (+0.03 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.45 | 234 | 11,103 | 987,351 | 987.1 K to 987.4 K (+0.02 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 46.97 | 2,359 | 110,798 | 10,793,451 | 10.8 M to 10.8 M (+0.02 %) |
Sep 08 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 46.97 | 185 | 8,689 | 987,117 | 986.9 K to 987.1 K (+0.02 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 49.08 | 83,832 | 4,114,734 | 10,791,092 | 10.7 M to 10.8 M (+0.78 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 49.08 | 6,645 | 326,157 | 986,932 | 980.3 K to 986.9 K (+0.68 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 48.74 | 2,286 | 111,430 | 10,707,260 | 10.7 M to 10.7 M (+0.02 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 48.74 | 181 | 8,823 | 980,287 | 980.1 K to 980.3 K (+0.02 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.74 | 42,714 | 2,039,256 | 10,704,974 | 10.7 M to 10.7 M (+0.40 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.74 | 3,386 | 161,655 | 980,106 | 976.7 K to 980.1 K (+0.35 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.82 | 754 | 36,058 | 10,662,260 | 10.7 M to 10.7 M (+0.01 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.82 | 60 | 2,869 | 976,720 | 976.7 K to 976.7 K (+0.01 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.72 | 41,155 | 1,963,970 | 10,661,506 | 10.6 M to 10.7 M (+0.39 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 47.72 | 3,262 | 155,667 | 976,660 | 973.4 K to 976.7 K (+0.34 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 46.50 | 10,640 | 494,716 | 10,620,351 | 10.6 M to 10.6 M (+0.10 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 46.50 | 843 | 39,196 | 973,398 | 972.6 K to 973.4 K (+0.09 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 46.30 | 3,576 | 165,575 | 10,609,711 | 10.6 M to 10.6 M (+0.03 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 46.30 | 283 | 13,103 | 972,555 | 972.3 K to 972.6 K (+0.03 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 46.99 | 3,585 | 168,447 | 10,606,135 | 10.6 M to 10.6 M (+0.03 %) |
Aug 21 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 46.99 | 284 | 13,344 | 972,272 | 972 K to 972.3 K (+0.03 %) |